{'fraction_non_alphanumeric': 0.016260162601626018, 'fraction_numerical': 0.0, 'mean_word_length': 5.432835820895522, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cancer Proteomics: How Far are We from the Clinics?

Abstract Cancer, in spite of several years of research and consequent improvements in clinical management of the disease, shows limited decline in the associated patient mortality and morbidity. In order to achieve better and early diagnosis, design appropriate treatment strategies and precise prognostication, molecular markers which could subclassify tumors are being assessed to complement TNM classification. Plethora of information is spilling out from the recent high-throughput technologies for global profiling. Time has come to assess the technologies, study designs and data processing to obtain information which is clinically relevant. This review analyses the state of the art in Cancer Proteomics and the issues, which need to be addressed to move the technology from the bench to the bedside.